TY - JOUR
T1 - Combination therapy with platinum and etoposide of brain metastases from breast carcinoma
AU - Cocconi, Giorgio
AU - Lottici, Renata
AU - Bisagni, Giancarlo
AU - Bacchi, Marisa
AU - Tonato, Maurizio
AU - Passalacqua, Rodolfo
AU - Boni, Corrado
AU - Belsanti, Virginio
AU - Bassi, Pellegrino
PY - 1990
Y1 - 1990
N2 - Twenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m2 day 1) and etoposide (100 mg/m2 days 4,6,8) every three weeks. Five (23% achieved a complete response (CR) while 7 (32% obtained a partial response (PR) for an overall response rate of 55% The 95% confidence interval for combined CR and PR was 34-76% Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12 + 152). Median duration of survival was 58 weeks (2; 208+ Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.
AB - Twenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m2 day 1) and etoposide (100 mg/m2 days 4,6,8) every three weeks. Five (23% achieved a complete response (CR) while 7 (32% obtained a partial response (PR) for an overall response rate of 55% The 95% confidence interval for combined CR and PR was 34-76% Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12 + 152). Median duration of survival was 58 weeks (2; 208+ Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0025059696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025059696&partnerID=8YFLogxK
U2 - 10.3109/07357909009012049
DO - 10.3109/07357909009012049
M3 - Article
C2 - 2207757
AN - SCOPUS:0025059696
VL - 8
SP - 327
EP - 334
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 3-4
ER -